FELODIPINE (Page 3 of 4)

Nursing Mothers

It is not known whether this drug is secreted in human milk and because of the potential for serious adverse reactions from felodipine in the infant, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Use

Safety and effectiveness in pediatric patients have not been established.

Geriatric Use:

Clinical studies of felodipine did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. Pharmacokinetics, however, indicate that the availability of felodipine is increased in older patients (see CLINICAL PHARMACOLOGY, Geriatric Use). In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.


In controlled studies in the United States and overseas, approximately 3000 patients were treated with felodipine as either the extended-release or the immediate-release formulation.

The most common clinical adverse events reported with felodipine extended-release tablets administered as monotherapy at the recommended dosage range of 2.5 mg to 10 mg once a day were peripheral edema and headache. Peripheral edema was generally mild, but it was age and dose related and resulted in discontinuation of therapy in about 3% of the enrolled patients. Discontinuation of therapy due to any clinical adverse event occurred in about 6% of the patients receiving felodipine extended-release tablets, principally for peripheral edema, headache, or flushing.

Adverse events that occurred with an incidence of 1.5% or greater at any of the recommended doses of 2.5 mg to 10 mg once a day (felodipine extended-release tablets, N = 861; Placebo, N = 334), without regard to causality, are compared to placebo and are listed by dose in the table below. These events are reported from controlled clinical trials with patients who were randomized to a fixed dose of felodipine extended-release tablets or titrated from an initial dose of 2.5 mg or 5 mg once a day. A dose of 20 mg once a day has been evaluated in some clinical studies. Although the antihypertensive effect of felodipine extended-release tablets is increased at 20 mg once a day, there is a disproportionate increase in adverse events, especially those associated with vasodilatory effects (see DOSAGE AND ADMINISTRATION).

Percent of Patients with Adverse Events in Controlled Trials* of Felodipine Extended-Release Tablets (N=861) as Monotherapy without Regard to Causality (Incidence of discontinuations shown in parentheses)
Body SystemAdverse Events PlaceboN=3342.5 mgN=2555 mgN=58110 mgN=408
Body as a Whole
Peripheral Edema3.3 (0.0)2.0 (0.0)8.8 (2.2)17.4 (2.5)
Asthenia3.3 (0.0)3.9 (0.0)3.3 (0.0)2.2 (0.0)
Warm Sensation0.0 (0.0)0.0 (0.0)0.9 (0.2)1.5 (0.0)
Palpitation2.4 (0.0)0.4 (0.0)1.4 (0.3)2.5 (0.5)
Nausea1.5 (0.9)1.2 (0.0)1.7 (0.3)1.0 (0.7)
Dyspepsia1.2 (0.0)3.9 (0.0)0.7 (0.0)0.5 (0.0)
Constipation0.9 (0.0)1.2 (0.0)0.3 (0.0)1.5 (0.2)
Headache10.2 (0.9) 10.6 (0.4) 11.0 (1.7) 14.7 (2.0)
Dizziness2.7 (0.3)2.7 (0.0)3.6 (0.5)3.7 (0.5)
Paresthesia1.5 (0.3)1.6 (0.0)1.2 (0.0)1.2 (0.2)
Upper Respiratory Infection1.8 (0.0)3.9 (0.0)1.9 (0.0)0.7 (0.0)
Cough0.3 (0.0)0.8 (0.0)1.2 (0.0)1.7 (0.0)
Rhinorrhea0.0 (0.0)1.6 (0.0)0.2 (0.0)0.2 (0.0)
Sneezing0.0 (0.0)1.6 (0.0)0.0 (0.0)0.0 (0.0)
Rash0.9 (0.0)2.0 (0.0)0.2 (0.0)0.2 (0.0)
Flushing0.9 (0.3)3.9 (0.0)5.3 (0.7)6.9 (1.2)

Adverse events that occurred in 0.5 up to 1.5% of patients who received felodipine extended-release tablets in all controlled clinical trials at the recommended dosage range of 2.5 mg to 10 mg once a day, and serious adverse events that occurred at a lower rate, or events reported during marketing experience (those lower rate events are in italics) are listed below. These events are listed in order of decreasing severity within each category, and the relationship of these events to administration of felodipine extended-release tablets is uncertain: Body as a Whole: Chest pain, facial edema, flu-like illness; Cardiovascular: Myocardial infarction, hypotension , syncope, angina pectoris, arrhythmia , tachycardia, premature beats; Digestive: Abdominal pain, diarrhea, vomiting, dry mouth, flatulence, acid regurgitation; Endocrine: Gynecomastia; Hematologic: Anemia; Metabolic: ALT (SGPT) increased; Musculoskeletal: Arthralgia, back pain, leg pain, foot pain, muscle cramps, myalgia, arm pain, knee pain, hip pain; Nervous/Psychiatric: Insomnia, depression, anxiety disorders, irritability, nervousness, somnolence, decreased libido; Respiratory: Dyspnea, pharyngitis, bronchitis, influenza, sinusitis, epistaxis, respiratory infection; Skin: Angioedema , contusion, erythema, urticaria, leukocytoclastic vasculitis ; Special Senses: Visual disturbances; Urogenital: Impotence, urinary frequency, urinary urgency, dysuria, polyuria.

Gingival Hyperplasia — Gingival hyperplasia, usually mild, occurred in < 0.5% of patients in controlled studies. This condition may be avoided or may regress with improved dental hygiene. (See PRECAUTIONS, Information for Patients.)

All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2022. All Rights Reserved.